Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company
Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company
Key Insights
关键洞察
- Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable to their trading decisions
- A total of 22 investors have a majority stake in the company with 51% ownership
- Recent sales by insiders
- 鉴于机构在股票中的大额股份,爱德华生命科学的股价可能会受到他们交易决策的影响。
- 共有22位投资者在该公司拥有多数股份,持股51%。
- 高管近期的卖出行为
Every investor in Edwards Lifesciences Corporation (NYSE:EW) should be aware of the most powerful shareholder groups. With 85% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
每位在爱德华生命科学公司(纽交所:EW)投资的股东都应该意识到最强大的股东群体。机构以85%的股份持有公司最多的股票。换句话说,該群体从对公司的投资中获得的收益(或损失)最大。
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
由于机构拥有大量资金和研究能力,机构持股在个别投资者中往往具有很大的影响力。因此,投资者在一家公司拥有相当数量的机构资金通常被视为一个可取的特征。
Let's delve deeper into each type of owner of Edwards Lifesciences, beginning with the chart below.
让我们深入探讨爱德华生命科学每种所有者的类型,从下面的图表开始。
What Does The Institutional Ownership Tell Us About Edwards Lifesciences?
机构持股情况告诉我们关于Edwards Lifesciences的什么信息?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与一个常见的指数回报进行比较。因此,他们通常会考虑购买纳入相关基准指数的大型公司股票。
As you can see, institutional investors have a fair amount of stake in Edwards Lifesciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Edwards Lifesciences, (below). Of course, keep in mind that there are other factors to consider, too.
正如您所见,机构投资者在爱德华生命科学中持有相当数量的股份。这意味着为这些机构工作的分析师对该股票进行了研究,并且他们喜欢它。但是,就像其他任何人一样,他们也可能是错的。如果两个大型机构投资者同时试图卖出一只股票,股价大幅下跌并不罕见。因此,查看爱德华生命科学过去的收益轨迹是值得的(见下文)。当然,记住还有其他因素需要考虑。
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Edwards Lifesciences. Looking at our data, we can see that the largest shareholder is The Vanguard Group, Inc. with 11% of shares outstanding. For context, the second largest shareholder holds about 9.3% of the shares outstanding, followed by an ownership of 5.3% by the third-largest shareholder.
投资者应注意,机构实际上拥有公司超过一半的股份,因此他们可以集体发挥显著的影响力。对冲基金在爱德华生命科学的股份并不多。根据我们的数据,最大的股东是先锋集团,持有11%的流通股份。作为背景,第二大股东持有约9.3%的流通股份,第三大股东则持有5.3%的股份。
After doing some more digging, we found that the top 22 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.
经过进一步挖掘,我们发现前22名股东共计拥有公司51%的股份,这表明没有单一股东对公司拥有显著的控制权。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
虽然研究一家公司的机构持股数据是有意义的,但研究分析师的情绪以了解市场趋势同样也是有意义的。现在有相当多的分析师关注这只股票,因此了解他们对未来的整体看法可能会很有用。
Insider Ownership Of Edwards Lifesciences
Edwards Lifesciences的内部所有权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
虽然对内幕人的确切定义可能是主观的,但几乎所有人都认为董事会成员是内幕人。公司管理层向董事会负责,后者应该代表股东的利益。值得注意的是,有时候高层管理者自己也是董事会成员。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部人拥有股份是一件好事。然而,在某些情况下,这使得其他股东更难让董事会对决策负责。
Our most recent data indicates that insiders own less than 1% of Edwards Lifesciences Corporation. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$399m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我们最新的数据表明,内部人士拥有爱德华生命科学公司不到1%的股份。由于它是一家大公司,我们只期待内部人士持有小部分股份。但值得注意的是,他们拥有价值39900万美元的股份。看到至少一些内部人士的持股总是好的,但可能值得检查这些内部人士是否在出售。
General Public Ownership
公众持股
The general public, who are usually individual investors, hold a 14% stake in Edwards Lifesciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
公众,通常是个人投资者,持有爱德华生命科学14%的股份。虽然这部分持股相当可观,但如果该决策与其他大型股东不同,这可能不足以改变公司政策。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Edwards Lifesciences better, we need to consider many other factors.
始终值得考虑不同的群体谁拥有公司的股票。但要更好地了解爱德华生命科学,我们需要考虑许多其他因素。
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
我喜欢深入了解一家公司过去的表现。您可以免费访问这张互动图表,查看过去的盈利、营业收入和现金流。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你像我一样,你可能想考虑这家公司是会增长还是缩小。幸运的是,你可以查看这份免费的报告,了解分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是根据过去十二个月的数据计算得出的,指的是截至财务报表日期的月份最后一天的12个月期间。这可能与完整年度的年报数字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。
译文内容由第三方软件翻译。